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Dicationic diamidines, such as diminazene and pentamidine, are well-studied chemotherapeutic agents with
significant activity against parasitic diseases. The in vitro activities of novel diamidine compounds against the
Babesia divergens strains 1903B and 4201 were investigated. The most potent compound, a diphenyl furan, had
a 50% inhibitory concentration (IC50) of 1.5 ng/ml. In a murine model, several test compounds were effective
enough to cure mice infected with Babesia microti at a dose of 12.5 and/or 25 mg/kg of body weight given by the
subcutaneous route for 4 days. The best antibabesial properties were exhibited by terphenyls, benzimidazoles,
diphenyl furans, pentamidine, and pentamidine analogues.
Babesiosis is a tick-borne infection caused by intraerythro-
cytic protozoan parasites of the genus Babesia and affects wild
and domestic animals worldwide. It is a well-known disease of
veterinary importance in cattle, horses, and dogs which causes
considerable economic losses in livestock industry and is gain-
ing interest as an emerging zoonosis. Bovine disease is most
common in tropical and subtropical regions (Babesia bovis,
Babesia bigemina), but infections are also seen in Europe
(Babesia divergens, Babesia major). Clinical manifestations like
fever, malaise, hemolytic anemia, and hemoglobinuria may be
absent, but babesiosis can develop into a severe, rapidly fatal
disease. Even though a number of effective antibabesial drugs
exist, they are not readily available in all areas due to safety,
residue, or marketing issues. The most widely used babesi-
acides are imidocarb dipropionate and diminazene aceturate;
however, only imidocarb is able to consistently clear the host of
parasites and has chemoprophylactic properties (29). Thus,
concerns about development of resistance are growing, and the
need for alternative compounds for the veterinary market is
evident.
Human infections with Babesia species have been known
since the late 1950s. While in Europe the causative agent in
cases of babesiosis in splenectomized individuals was identified
as the cattle species B. divergens, the rodent species Babesia
microti was reported in most cases of human babesiosis in
North America (8, 14, 28), where the disease is endemic and
transmitted by the tick Ixodes damiani (also known as I. scapu-
laris). Babesia duncani and B. divergens-like organisms later
attracted attention in the west and midwest of the United
States. Sporadic cases of human babesiosis have also been
identified in Asia, Africa, and South America (28).
Diamidines have a long history as chemotherapeutic agents
against protozoan infections, and their synthetic producibility,
as well as their low molecular weight, makes them an attractive
drug class. The activity is due mostly to the selective accumu-
lation by the parasite rather than the host cell. Aromatic di-
cationic molecules are thought to act by binding to the minor
groove of DNA at AT-rich sites, which are present in many
parasitic organisms, and thus they may possibly inhibit DNA-
dependent enzymes or cause direct inhibition of transcription
(26). In previous studies, the significant antiparasitic activity of
novel diamidines against Trypanosoma brucei and Plasmodium
spp. has been shown (2, 15, 25, 26).
In the present study, we selected new diamidine compounds
according to their in vitro activities against Plasmodium falcip-
arum and demonstrated their in vitro potential against the two
B. divergens strains 1903B and 4201. Subsequently, a selection
of compounds was evaluated in a B. microti mouse model.
MATERIALS AND METHODS
Parasite strains and cultivation. The two bovine B. divergens strains 1903B and
4201 were kindly provided by Laurence Malandrin of the Ecole Nationale
Vétérinaire de Nantes, Nantes, France. Continuous in vitro cultures were main-
tained in human red blood cells (RBC) diluted to 5% hematocrit in RPMI 1640
with 25 mM HEPES and 2 mM glutamine (BioConcept, Allschwil, Switzerland)
supplemented with 5 g/liter Albumax I (Gibco/BRL Life Technologies, Belgium)
and 10 g/liter gentamicin (Sigma, Steinheim, Germany). All cultures were kept
in 25-ml flasks at 37°C in a 4% CO2, 3% O2, 93% N2 gas mix. The medium was
changed daily, and subpassages were performed every 2 to 3 days when the
parasitemia reached 20%.
The strain of B. microti was kindly donated by Lise Gern (University of
Neuchatel, Neuchatel, Switzerland). It was isolated from a bank vole (Myodes
glareolus) in Central Switzerland and finally maintained by passages in female
Swiss NMRI mice. The animals were sacrificed when the parasitemia reached
20%, and blood was collected by cardiac puncture. The course of infection was
investigated using different infective doses. After intravenous inoculation with
2  107 B. microti-infected RBCs, mice typically showed a peak parasitemia of 70
to 80% by day 7 and a subsequent decrease to low or undetectable values by
day 50.
Antibabesial agents. The diamidines were synthesized in the laboratories of
David Boykin and Richard Tidwell as previously described (5, 11, 13). The
syntheses of the unpublished compounds were achieved in an analogous manner.
For in vitro studies, stocks of 10 mg/ml were prepared in dimethyl sulfoxide
(DMSO) and subsequently diluted in RPMI cultivation medium, whereas for in
vivo studies, compounds were dissolved in a 10% DMSO-water solution. Dimi-
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nazene aceturate (Berenil; Sigma, Steinheim, Germany), imidocarb dipropionate
(Carbesia; Schering-Plough, kindly donated by Pierre Bonnemain), and atova-
quone (GSK, Muenchenbuchsee, Switzerland) served as standard drugs. Stan-
dards were prepared as described above except for imidocarb dipropionate, a
sterile solution that was diluted directly in RPMI or sterile deionized water.
Cytotoxicity determination. Cytotoxicity for L6 rat skeletal myoblasts was
determined using the Alamar blue assay as described earlier (7, 21, 23).
In vitro growth-inhibitory assay. Growth inhibition was determined by mea-
suring the incorporation of radiolabeled [8-3H]hypoxanthine (GE Healthcare,
Amersham, United Kingdom) as described before (4). Twofold serial drug di-
lutions were prepared in 96-well microtiter plates in order to test seven drug
concentrations to determine the 50% inhibitory concentrations (IC50s). Dupli-
cate wells received 100 l of drug dilution and 100 l of human RBC (2%
parasitemia, 2.5% hematocrit). Controls consisted of infected RBCs without
drug and noninfected RBCs. Plates were incubated at 37°C in a 4% CO2, 3% O2,
93% N2 atmosphere for 48 h. Then 50 l [8-3H]hypoxanthine was added (0.5
Ci/well), and plates were incubated for another 24 h. Cells were then harvested
on glass fiber filters with a cell harvester (Betaplate; Wallac PerkinElmer, Swit-
zerland), the incorporated radioactivity was counted in a liquid scintillation
counter (Betaplate; Wallac PerkinElmer, Switzerland), and IC50s were calcu-
lated.
In vivo drug susceptibility test. Female Swiss NMRI mice (18 to 20 g; RCC,
Switzerland) were used for in vivo drug tests. On day 0, groups of three mice each
were inoculated intravenously with 2  107 B. microti-infected RBCs. Diamidine
compounds and standard drugs were administered subcutaneously or orally
(atovaquone) in intervals of 4, 24, 48, and 72 h postinfection. Doses ranged from
50 to 12.5 mg/kg of body weight in a volume of 10 ml/kg. All experiments
included a group of untreated controls. Tail blood was collected at least twice a
week starting on day 7. Blood smears were stained with Giemsa, and parasitemia
was determined microscopically with a detection limit of 1 parasite in 10,000
erythrocytes. A compound was defined as curative if no parasites were detectable
up to day 60.
RESULTS
Different chemical classes of diamidines were screened for
activity against B. divergens in vitro and B. microti in vivo and
compared to the standard drugs diminazene aceturate, imido-
carb dipropionate, and atovaquone. The results are summa-
rized in Tables 1 and 2.
In vitro activity against B. divergens. The dicationic mole-
cules demonstrated a high selectivity for B. divergens compared
to their cytotoxicity for mammalian cells, which was tested
using L6 rat myoblast cells in an Alamar blue assay (7, 21, 23).
Of the 214 diamidine compounds, 80 showed excellent IC50s
below 20 ng/ml, comparable to the in vitro activities of the
standard antibabesial agents, but were up to 10 times more
active than those agents. The best inhibitory effects on the
growth of the cultured parasites were demonstrated by the
benzimidiazoles, diphenyl furans, and indoles (Table 1). It is
noteworthy that almost exclusively compounds of the class of
the benzimidazoles also showed high in vitro activity against
both Plasmodium falciparum and Trypanosoma brucei rhod-
esiense (data not presented).
In vivo activity against B. microti. NMRI mice infected with
2  107 parasitized mouse RBCs typically developed a peak
parasitemia of 70 to 80% by day 7 postinfection followed by a
second smaller peak of 20 to 25% around day 15. Subse-
quently, the parasitemia decreased to low and undetectable
values (Fig. 1). The standard drugs diminazene at 25 mg/kg
and imidocarb at 12.5 mg/kg administered on four consecutive
days did not cure the mice but resulted in a delayed para-
sitemia peak of approximately 50% around day 23 followed by
a decrease to 5% or less by day 30 postinfection. Most of the
compounds tested in vivo were potent enough to cause rapid
suppression and initial clearance of parasites from the blood by
day 10 at a dosage of 25 mg/kg subcutaneously for the first 4
days. Failure to cure resulted in recrudescence by day 30, and
peak parasitemia was generally seen 5 to 10 days after the
relapse.
The best antibabesial properties were exhibited by the ter-
phenyls, benzimidazoles, diphenyl furans, and pentamidine
and its analogues as well as a diaryldiamidine (Table 2).
Three terphenyls provided cures of 2/3 (23DAP055,
19DAP085) or 3/3 (19DAP025) mice at a dosage of 25 mg/kg
administered for 4 days. At a lower dose of 12.5 mg/kg,
19DAP025 still showed excellent activity and yielded a 3/3
cure.
The tested benzimidazoles were either very efficient in elim-
inating the parasites or could not reduce the parasite load
significantly. DB818 and 6KXR030 cured 3/3 mice at a dosage
of 25 mg/kg subcutaneously for 4 days. Administration of 12.5
mg/kg for 4 days resulted in a 2/3 cure for 6KXR030; however,
in the case of DB818, all mice showed recrudescence around
day 20 postinfection. DB942 and DB921 provided 100%
suppression on day 10 but did not suppress parasitemia after
day 18.
The diphenyl furan DB75, also known as furamidine, had
excellent antibabesial activity when given subcutaneously. Four
doses at 25 mg/kg cured all mice; at 20 mg/kg, 2/3 mice were
cured, and at 12.5 mg/kg, 1/3 was cured. Even at lower doses,
DB75 suppressed parasitemia completely through day 13 (6.25
mg/kg) or reduced parasitemia by 99% by day 7 (3.125 mg/
kg). Mice treated with other diphenyl furans (DB530, DB555,
and DB930) showed no detectable parasitemia until 10 days
after the last of four injections of 25 mg/kg, but then parasites
gradually reemerged.
Pentamidine is well known for its broad-spectrum antimi-
crobial activity, including antibabesial properties (24). In the
series of pentamidine and pentamidine analogues, two com-
pounds provided cures at 25 mg/kg: the pentamidine HCl
3SLT057 (1/3 cure) and the analogue 3KEG083 (3/3 cure).
The isoxazoles and thiophenes did not show very good po-
tency against B. microti. Although most of them caused a
decrease in parasitemias to 1% by day 7, only one compound
in each series could initially clear the parasites, and all mice
had relapsed by day 17.
Further chemical groups tested only in small numbers in-
cluded guanidino indenes, aza-furans, and biphenyls. All three
groups seemed to bear considerable antibabesial potential.
When administered subcutaneously on four consecutive days
at 25 mg/kg, DB905A, DB820C, and DB986 cured 3/3, 2/3, and
1/3 mice, respectively.
In comparison with the diamidine compounds, the standard
drugs were not particularly effective (Fig. 1). Even at a dosage
of 50 mg/kg for 4 days, diminazene treatment resulted in a
pronounced relapse. Atovaquone only reduced the parasite
burden and slightly delayed the peak parasitemia. Only imido-
carb dipropionate provided a 2/3 cure at a dosage of 25 mg/kg
for 4 days.
Correlation of in vitro activity and in vivo efficacy. Of the 25
compounds with low IC50s (20 ng/ml) tested in vivo against B.
microti, 6 caused clearance of the parasites in one or more
mice. A comparable number (7/30) of compounds with IC50s in
the middle range (20 to 85 ng/ml) could also eliminate B.
microti from the blood.
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TABLE 1. In vitro antibabesial and cytotoxic activities of diamidines
Compound











DB 0103 (5) Diphenyl furan 457.00 0.0015 0.0017 82.27
DB 1193b Diaryl diamidine 553.00 0.0016 0.0026 19.2
48–702 Benzimidazole 654.64 0.0017 0.0018 26.7
DB 0940 (1) Benzimidazole 583.40 0.0020 0.0021 65.5
DB 1191b Indole 425.35 0.0021 0.0020 6.8
DB 1172b Indole 402.30 0.0022 0.0021 1.8
DB 0921 (11) Benzimidazole 566.00 0.0023 0.0027 9.6
DB 1250 (11) Benzimidazole 581.80 0.0025 0.0020 15.07
DB 1236 (11) Benzimidazole 575.00 0.0027 0.0034 17.71
DB 0922 (11) Benzimidazole 541.00 0.0030 0.0035 13.8
DB 1190b Indole 489.4 0.0030 0.0039 64.6
DB 0942 (11) Benzimidazole 575.90 0.0035 0.0026 12.6
DB 1197b Benzimidazole 581.50 0.0037 0.0054 42.7
DB 1171 (27) Indole 354.75 0.0042 0.0038 0.6
Continued on following page
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DISCUSSION
The results presented in this study demonstrate that a
variety of diamidines possess in vitro and in vivo antibabesial
activities equal or superior to those of the existing drugs
(diminazene aceturate, imidocarb dipropionate, and atova-
quone).
The in vitro data with IC50s of less than 10 ng/ml reflect the
great antiprotozoal potential of the dications that had already
been found against other protozoan parasites. A clear corre-
lation between in vitro activities of the diamidines against B.
divergens, P. falciparum, and T. brucei rhodesiense, however,
was not evident. A fourth of the tested compounds showed
IC50s that were very similar to those of P. falciparum, and
another fourth showed IC50s that were very similar to those of
T. brucei rhodesiense. Nevertheless, only a very limited number
demonstrated comparable activity against all three parasites
TABLE 1—Continued
Compound











40–278 Benzimidazole 677.42 0.0048 0.0046 57.1
DB 0755b Benzimidazole 636.10 0.0049 0.0051 13.2
DB 0818 (19) Benzimidazole 474.00 0.0049 0.0051 10.6
DB 0192 (6) Benzimidazole 546.80 0.0052 0.0159 90
DB 0988 (11) Benzimidazole 553.00 0.0054 0.0058 14.6
DB 0558 (3) Diphenyl furan 474.50 0.0055 0.0050 87.1
Imidocarb Standard drug 348.4 0.0106 0.0112 ND
Diminazene
(diaceturate) Standard drug 515.5 0.0158 0.0149 ND
Atovaquone Standard drug 366.8 0.0091 0.0087 ND
a The IC50s are mean values for at least two replicates. ND, not done.
b Not published.
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TABLE 2. Activities of diamidine compounds and standard drugs against B. microti in NMRI mice and B. divergens in vitro














Terphenyls 19DAP025 25, 12.5 3/3, 3/3 0.0331 0.0318
23DAP055 25 2/3 0.0633 0.0717
19DAP085 25 2/3 0.0457 0.0446
Benzimidazoles 6KXR030 25, 12.5 3/3, 2/3 0.0081 0.0096
DB818 (19) 25 3/3 0.0049 0.0051
DB942 (11) 50 2/2 0.0035 0.0026
DB988 (11) 50 1/2 0.0054 0.0058
Diphenyl furan DB75 (5) 25, 20, 15, 12.5 3/3, 2/3, 1/3, 1/3 0.0112 0.0109
Pentamidine/
analogues 3KEG083 25 3/3 0.0101 0.0108
3SLT057 25 1/3 0.0329 0.0377
Guanidino indene DB905A (3) 25 3/3 0.0289 0.0314
Aza-furan DB820C (13) 25 2/3 0.0410 0.0413
Biphenyl DB986 (12) 25 1/3 0.0844 0.0903
Continued on following page
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(data not shown). Interestingly, most of those compounds be-
longed to the benzimidazoles. This result could suggest that
these parasites have common transporters which recognize the
amidino-benzimidazole motif.
In the B. microti mouse model, the test compounds were
considerably more active than the standard drugs. Diminazene
aceturate and imidocarb dipropionate are used for treatment
and prophylaxis of bovine, equine, canine, and ovine babesiosis
in the field, usually as an intramuscular or subcutaneous injec-
tion of 3 to 5 mg/kg. In our B. microti mouse model, dimina-
zene could not provide a cure at a 10-fold-higher dosage. In
previous studies, where different antiprotozoal drugs had been
screened against B. microti in Mongolian gerbils (24) and ham-
sters (20), diminazene was one of the most active drugs tested.
Imidocarb, though more effective than diminazene, yielded
only 2/3 cures at 25 mg/kg for 4 days, while several of the
diamidines provided 3/3 cures. To our knowledge, there are no
similar studies published where the efficacy of imidocarb was
tested in B. microti mouse models, which is probably due to the
fact that imidocarb is not licensed for human use. With atova-
quone we expected to see a higher efficacy, since the drug had
been reported to be very effective in B. microti-infected ham-
sters (10, 31) as well as in Mongolian gerbils infected with B.
microti (9) or B. divergens (22). It was suggested, though, that
B. divergens might be more sensitive than B. microti. In com-
paring our results with previous ones, it has to be considered
that we used a different animal species and different treatment
regimens. While in our study diminazene was administered at
50 mg/kg on four consecutive days, the Mongolian gerbils were
treated at 20 mg/kg over a period of 14 days to achieve a
complete eradication of the infection (24). Hughes and Oz
administered atovaquone at doses up to 300 mg/kg over 2
weeks to hamsters and reported survival at day 24, but para-
sites were not cleared at all doses. In a further study in ham-
sters where atovaquone was used as monotherapy, recrudes-
cences with the emergence of resistant organisms were
described. Resistance could be prevented by the addition of
TABLE 2—Continued














Standards Imidocarb 25, 12.5 2/3, 0/3 0.0106 0.0112
Diminazene 50 0/0 0.0158 0.0149
Atovaquone 25 0/0 0.0091 0.0087
a All doses were given subcutaneously for 4 days.
b Results are given as number of cured animals/number of infected animals.
c The IC50s are mean values for at least two replicates.
FIG. 1. Parasitemia in mice infected with B. microti in an untreated
control group and after treatment with the standard drugs diminazene
(25 mg/kg) and imidocarb (12.5 mg/kg) and with diamidine 19DAP025
(12.5 mg/kg). The standard drugs led to a delayed parasitemia of
shorter duration than that for the untreated control, while the di-
amidine-treated mice were cured.
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azithromycin (31). The combination of atovaquone and
azithromycin is also used for the treatment of human babesi-
osis (17, 30). However, unlike the situation with P. falciparum
(16), there has been no evidence of treatment failure due to
resistant strains of B. microti (18) in humans. Nevertheless, for
further in vivo experiments in our B. microti mouse model,
combination treatments could provide valuable information.
The IC50 values of the in vivo active diamidines varied from
3.5 ng/ml to 60 ng/ml. This finding suggests that a low IC50
should not be the only selection criterion for in vivo testing, as
pharmacological parameters are as important as the antipara-
sitic activity. The ability of IC50s to predict in vivo activity is
problematic, and thresholds should not be set too low when
compounds are being selected for in vivo trials.
In conclusion, the data presented in this report indicate the
potential of dicationic aromatic molecules as antibabesial
agents. It is evident that further studies of structure-activity
relationships, mode of action, toxicity, and in vivo efficacy of
these compounds are needed before a clinical candidate can be
selected.
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